Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZTC -- Ignore unavailable to you. Want to Upgrade?

To: kinkblot who wrote (621)	9/27/1999 8:54:00 PM
From: kinkblot	Read Replies (1) \| Respond to of 752

Progenics Reports Positive Clinical Results For HIV Therapy see the September 27, 1999 news release at progenics.com Also see the February 18, 1998 release announcing the collaboration with Genzyme Transgenics to produce PRO 542 in the milk of transgenic animals. In their 1998 Form 10-K, page 11 (Business: HIV Therapeutics), Progenics says: This collaboration is designed to result in commercial-scale manufacture by expressing PRO 542 in the milk of transgenic goats. By establishing this production arrangement, Progenics can potentially advance PRO 542's development through Phase III clinical trials without the need for a commercialization collaboration. The above shows how transgenic production can help reduce the financial pressure on a small company like Progenics. Reference to the collaboration is included in all of Progenics' PRO 542 news releases, but the current status of the program hasn't been discussed.